PCN20 THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

May 1, 2009, 00:00
10.1016/S1098-3015(10)73257-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)73257-5/fulltext
Title : PCN20 THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73257-5&doi=10.1016/S1098-3015(10)73257-5
First page :
Section Title :
Open access? : No
Section Order : 676
Categories :
Tags :
Regions :
ViH Article Tags :